Cytosorbents (NASDAQ:CTSO) CEO Phillip Chan Acquires 3,774 Shares of Stock

Cytosorbents Corporation (NASDAQ:CTSO) CEO Phillip Chan purchased 3,774 shares of the stock in a transaction dated Tuesday, September 15th. The stock was acquired at an average cost of $6.00 per share, for a total transaction of $22,644.00. Following the transaction, the chief executive officer owned 100,996 shares of the company’s stock, valued at approximately $605,976. This trade represents a 3.88% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Cytosorbents Stock Down 5.4%

CTSO opened at $5.73 on Thursday. Cytosorbents Corporation has a 12 month low of $5.13 and a 12 month high of $20.40. The company has a market cap of $18.05 million, a PE ratio of -0.99 and a beta of 1.34. The company has a current ratio of 0.66, a quick ratio of 0.50 and a debt-to-equity ratio of 4.70. The company has a 50 day moving average of $7.15 and a 200 day moving average of $9.77.

Cytosorbents (NASDAQ:CTSO) last issued its earnings results on Thursday, August 6th. The medical research company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.73. Cytosorbents had a negative net margin of 48.94% and a negative return on equity of 431.65%. The business had revenue of $9.63 million for the quarter, compared to analysts’ expectations of $9.38 million. On average, sell-side analysts expect that Cytosorbents Corporation will post -4.4 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cytosorbents in a report on Monday, July 6th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $107.50.

Cytosorbents Company Profile

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.